Monopar Therapeutics (NASDAQ:MNPR) Receives “Hold” Rating from Jones Trading

Jones Trading reiterated their hold rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report sent to investors on Wednesday,Benzinga reports.

MNPR has been the subject of several other research reports. Piper Sandler restated an “overweight” rating and issued a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $38.53 on Wednesday. The firm has a market cap of $235.11 million, a PE ratio of -19.56 and a beta of 1.18. The firm has a 50 day simple moving average of $38.61 and a 200-day simple moving average of $24.63. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87). As a group, sell-side analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MNPR. JPMorgan Chase & Co. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $45,000. Geode Capital Management LLC raised its stake in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth $2,861,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Monopar Therapeutics in the fourth quarter valued at $13,182,000. Finally, RA Capital Management L.P. acquired a new stake in Monopar Therapeutics during the 4th quarter valued at $11,247,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.